Assembly Biosciences Inc logo

ASMB - Assembly Biosciences Inc Share Price

$14.45 -0.6  -4.0%

Last Trade - 27/03/20

Sector
Healthcare
Size
Mid Cap
Market Cap £378.5m
Enterprise Value £158.5m
Revenue £12.8m
Position in Universe 2645th / 6324
Bullish
Bearish
Unlock ASMB Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ASMB Revenue Unlock ASMB Revenue

Net Income

ASMB Net Income Unlock ASMB Revenue

Normalised EPS

ASMB Normalised EPS Unlock ASMB Revenue

PE Ratio Range

ASMB PE Ratio Range Unlock ASMB Revenue

Dividend Yield Range

ASMB Dividend Yield Range Unlock ASMB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ASMB EPS Forecasts Unlock ASMB Revenue
Profile Summary

Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated October 7, 2005
Public Since December 17, 2010
No. of Shareholders: 80
No. of Employees: 115
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 32,624,725
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ASMB Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ASMB
Upcoming Events for ASMB
Similar to ASMB
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.